Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer.
Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer.